Johnson & Johnson (JNJ) Goodwill & Intangibles (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Goodwill & Intangibles came in at $97.6 billion in Q1 2026, up 20.19% year-on-year from $81.2 billion in Q1 2025, and down 1.57% quarter-over-quarter from $99.2 billion in Q4 2025.
Johnson & Johnson (JNJ) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Goodwill & Intangibles across 18 years of filings, most recently posting $97.6 billion for Q1 2026.
- Goodwill & Intangibles for Q1 2026 came in at $97.6 billion, up 20.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $97.6 billion (up 20.19% YoY), and the FY2025 annual result was $99.2 billion, up 21.21% from the prior year.
- Goodwill & Intangibles came in at $97.6 billion for Q1 2026 at Johnson & Johnson, down from $99.2 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $99.2 billion in Q4 2025 to a low of $70.7 billion in Q4 2023.
- The 5-year median for Goodwill & Intangibles is $81.5 billion (2024), against an average of $83.1 billion.
- Across the five-year window, Goodwill & Intangibles soared 54.66% in 2022 and declined 23.78% in 2024, its largest moves.
- Johnson & Johnson's Goodwill & Intangibles stood at $73.7 billion in 2022, then retreated by 4.05% to $70.7 billion in 2023, then advanced by 15.67% to $81.8 billion in 2024, then climbed by 21.21% to $99.2 billion in 2025, then slipped by 1.57% to $97.6 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $97.6 billion (Q1 2026), $99.2 billion (Q4 2025), and $96.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 97.62 Bn |
| Dec 28, 2025 | 99.18 Bn |
| Sep 28, 2025 | 96.79 Bn |
| Jun 29, 2025 | 97.95 Bn |
| Mar 30, 2025 | 81.22 Bn |
| Dec 29, 2024 | 81.82 Bn |
| Sep 29, 2024 | 84.29 Bn |
| Jun 30, 2024 | 83.98 Bn |
| Mar 31, 2024 | 70.90 Bn |
| Dec 31, 2023 | 70.73 Bn |
| Oct 1, 2023 | 71.15 Bn |
| Jul 2, 2023 | 91.69 Bn |
| Apr 2, 2023 | 93.02 Bn |
| Jan 1, 2023 | 74.54 Bn |
| Oct 2, 2022 | 73.72 Bn |
| Jul 3, 2022 | 76.57 Bn |
| Apr 3, 2022 | 79.36 Bn |
| Jan 2, 2022 | 71.83 Bn |
| Oct 3, 2021 | 83.35 Bn |
| Jul 4, 2021 | 86.06 Bn |